Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Markus F. Renschler(Princess Margaret Cancer Centre), J. Mezger(Heidelberg University), Martin Steins(Heidelberg University), Kristiaan Nackaerts(Heidelberg University), Robert M. Jotte(Sarah Cannon), Leon Bosquée(Heidelberg University), Martin Reck(German Center for Lung Research), José Trigo(Heidelberg University), Paul Lorigan(Manchester Academic Health Science Centre), Frances A. Shepherd(University Health Network), Mark A. Socinski(Florida Hospital Cancer Institute), Manuel Dómine(Chinese Academy of Medical Sciences & Peking Union Medical College), Jeffrey A. Bubis(Heidelberg University), Shaoyi Li(St. Jude Children's Research Hospital), Wolfgang Schütte(Martha-Maria Hospital), Mary O’Brien(Royal Marsden NHS Foundation Trust), Philip Clingan(Heidelberg University), David R. Spigel(Sarah Cannon)
Cited by 344
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k